 Provider News New YorkSeptember 2023 Provider Newsletter Contents
NYBCBS-CDCRCM-035546-23 Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Availity, LLC is an independent company providing administrative support services on behalf of the health plan. Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. As part of our ongoing quality improvement efforts, we want you to know that some review requests may require documentation to substantiate the attestations that support the clinical appropriateness of the request. This documentation can be uploaded during the intake process. When requested, providers must submit such documentation from the patient’s medical record. If medical necessity is not supported through documents submitted, the request may be denied as not medically necessary. Such documentation is limited to what has been asserted via the prior authorization (PA) review attestations. If the request would be denied as not medically necessary, providers can participate in a PA discussion with an Carelon Medical Benefits Management physician reviewer. * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. NYBCBS-CM-034176-23-CPN34175 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. We ask that you review your online provider directory information on a regular basis to ensure it is correct. Access your information by visiting empireblue.com/provider, then under Provider Overview, choose Find Care. The Consolidated Appropriations Act (CAA) of 2021 contains a provision that requires online provider directory information be reviewed and updated as needed at least every 90 days. By reviewing your information regularly, you help us ensure your online provider directory information is current. Submit updates and corrections to your directory information by following the instructions on our Provider Maintenance webpage. We will send you an email acknowledging receipt of your request. Online update options include: - Add/change an address location.
- Name change.
- Provider leaving a group or a single location.
- Phone/fax number changes.
- Closing a practice location.
NYBCBS-CM-034854-23-CPN34821 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. As a reminder, on January 1, 2024, Empire BlueCross BlueShield and Empire BlueCross will become Anthem Blue Cross and Blue Shield and Anthem Blue Cross. This will take place across Commercial, Medicaid, and Medicare lines of business. There will be no impact to your contract, reimbursement, or level of support. Why is Empire becoming Anthem?Empire joined the Anthem family of health plans in 2006. The decision to transition the name from Empire to Anthem brings together everything that the well-respected, industry-leading Anthem brand has to offer, with the strength and value of the Blue Cross and Blue Shield brand that generations of New Yorkers have come to know and trust. We will continue to combine the trust of the Blue Cross and Blue Shield name and the national resources and capabilities of our parent company and affiliates to improve the whole health of all New Yorkers. Below is a chart to summarize our recent and upcoming brand migrations. 
For you and your patients, our priority is to make this a simple, seamless transition, so patients can continue to use the same doctors and hospitals they do today: - Our care provider networks are not changing.
- Your patients’ plan, coverage, and ID card numbers are not changing. We will be sending out new ID cards starting this year and throughout 2024, and both the new Anthem-branded cards and old Empire-branded cards will be valid.
- We will still offer the same high-quality, affordable health benefits.
- We will continue to offer the same programs and services to help your patients take care of their overall health and well-being.
- Our existing Anthem-branded health plans in our other Blue-licensed markets are not changing and will continue to operate in their current states.
Keeping you well informed is a top priorityIn advance of our official launch on January 1, 2024, we will continue to communicate news and updates to our partners, customers, and members to help prepare for this transition. For more information, please read the Frequently Asked Questions and press release or visit empireblue.com/provider. For more information about our go-to-market brands (for example, Anthem), visit https://elevancehealth.com/who-we-are/companies. Thank you for being our trusted health partner. We look forward to building the future of healthcare together as Anthem Blue Cross and Blue Shield/Anthem Blue Cross. NYBCBS-CDCRCM-034700-23, NYBCBS-CDCRCM-038597-23, NYBCBS-CDCRCM-037455-23 ATTACHMENTS (available on web): Frequently Asked Questions (pdf - 0.22mb) Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. The article titled Notification about submitting itemized bills in the June 2023 edition of Provider News outlined a requirement for itemized bills for inpatient and outpatient services. The prior communication failed to clarify that the itemization will only be required to substantiate reimbursement to providers and facilities for services on claims paid by DRG with an outlier paid at percent of billed charge or where the entire claim is paid at percent of billed charge. We apologize for any confusion caused. Please note that these changes remain effective September 1, 2023. Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc., licensees of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. NYBCBS-CM-037073-23 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. The American Cancer Society (ACS) recommends annual fecal immunochemical test (FIT) kit testing for all adults aged 45 and older with average risk for colon cancer. For these patients, the FIT kit is a convenient, cost-effective, and discreet testing option.1, 2 FIT kits offer a cost-effective, highly accurate option for colorectal cancer screening Screening with FIT kits is convenient and easier than ever. Adopting FIT screening into your practice can help increase patient adherence to colon cancer screening recommendations. Annual FIT improves screening rates and has also been shown to save lives.3 Empire BlueCross BlueShield network physicians and their patients have access to high-quality, low-cost colorectal cancer screening FIT kits through our National Lab partners Labcorp and Quest Diagnostics.* If you have specific questions, please contact the labs directly: To find Labcorp, Quest Diagnostics, and other participating labs in your patient’s plan network, select Find Care from the Provider Resources menu at empireblue.com. References: 1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin.2018;68(4):250-281. 2. Occult blood, fecal, immunoassay. Laboratory Corporation of America Holdings and Lexi-Comp Inc. 2021. Accessed April 11, 2022.https://bit.ly/3pRHPlV. 3. Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(12):1645-1658.
* Quest Diagnostics is an independent company providing preventive care technology and health risk assessments services on behalf of the health plan. NYBCBS-CM-024719-23-CPN24527, NYBCBS-CM-034218-23 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective for all claims received on and after October 1, 2023, Empire BlueCross BlueShield (Empire) is updating its outpatient facility editing system to align with correct coding guidelines. For claims received on or after October 1, 2023, when revenue codes 0278, 0636, 0760, 0761, 0762, and 0769 are billed with an inappropriate HCPCS or CPT® code, they will be denied. For assistance with coding guidelines, please refer to CPT coding guidelines and Encoder Pro. If you believe you have received a denial in error, please follow the standard claim dispute process for Empire. Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. We understand that providing the information needed to process a claim can cause payment delays, and the manual methods associated with mailing letters and returning information non-digitally is costly and inefficient. We’re changing that by implementing a new process: Digital Request for Additional Information (Digital RFAI), and we’re inviting you to participate. Digital requests for additional information are 50% faster than returning documentation any other way — making it the most efficient way to receive and return information — resulting in faster claim payments. Participation in Digital RFAI is easy- Registration:
- Your organization’s Availity* administrator will register for Medical Attachments:
- This enables you to receive digital notices (instead of paper) and to attach the requested documents directly to your claim.
- Ensure all of your billing NPIs/TINs are registered.
- User roles:
- Your Availity administrator will also update or add new users with these specific role assignments through Availity Essentials:
- Claims Status
- Medical Attachments
- This enables the users to view the Availity Attachment Dashboard.
- Ready to go:
- After the registration and user roles are completed on Availity, the Digital RFAI process is ready to go.
- Requests will automatically appear on the Attachments Dashboard each morning (when documents are needed).
Additional supportYou, your organization’s Availity administrator, or other members of your team may need additional support – and we’re to help: - For Availity Administrators: Take this training to ensure your NPIs are registered properly.
- For those sending attachments: Take this user training to learn about accessing notifications, sorting and filtering, and other enhancements that improve your experience.
Through our efforts, we are committed to reducing administrative burden and ensuring timely payments because we value you, our care provider partner. For additional resources, visit the Digital RFAI webpage or contact your Provider Relations Account Manager. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. NYBCBS-CM-036133-23-CPN35203 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Description/Approach Provider performance can vary widely in relation to efficiency and quality. Our goal as your Medicare health plan partner is to ensure our members receive high-quality care that leads to improved member health outcomes across a wide range of variables. We will add a new sorting option on the Find Care tool for members to leverage when they are searching for a non-PCP specialist provider. This sorting option, called Personalized Match Phase 1, is based on each provider’s score relative to their peers in the patient’s preferred mileage search radius. Providers will be listed in order of their total score, though no individual scores will appear within the tool or be visible to the covered patients. The Personalized Match Phase 1 algorithm will be based on quality and efficiency criteria to assist members in making more informed choices about their medical care. Other sorting options will still be available on Find Care for our members. Members should consider a variety of factors when making decisions for choosing a specialist provider to manage their care. We evaluate provider groups and individual providers annually, using updated quality and efficiency methodologies and data. Continue reading the rest of this article * Optum is an independent company providing assessment and reporting services on behalf of the health plan. NYBCBS-CR-032274-23-CPN32264 ATTACHMENTS (available on web): Personalized Match Phase 1: Specialist Provider Overview (pdf - 0.61mb) Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Digital Request for Additional Information (Digital RFAI) is the fastest and easiest way to get us the documents we need to process your claim. Now, it is even better! We’ve added filter, sort, and search features for greater productivity. New filtering functions are ideal for organizations where more than one person is responsible for submitting claim attachments. Another great feature: your filters are saved (locked) – so you can see your desired filter view each time you log on but easily clear them when your search criteria changes.

We are committed to shared success and reporting is just another way we are giving Digital RFAI users a productivity boost. We’ve added reporting fields that can be used for both History and Inbox reports. Fields available for History and Inbox reports
Expanded reporting fields are downloadable! Use the download option to meet your specific reporting requirements. 
We’re here to help! Want to know more about receiving digital notifications for faster claims processing? Visit the Digital RFAI learning microsite or reach out to your Provider Relations Account Manager. NYBCBS-CM-035614-23-CPN35217 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Starting mid-September, search for patient information in Availity Essentials* Eligibility and Benefits without having a member ID. We’ve updated and streamlined the process to eliminate the need for the member ID while maintaining the highest HIPAA standards. Easily search for patient eligibility and benefits details using the Patient Search option of patient last name, patient first name, date of birth, and patient zip code. Find Eligibility and Benefits Inquiry on Availity’s top menu bar under Patient Registration. Once it becomes available, make sure to use the new search feature when you need to find member information and do not have access to the member ID. Need the member ID for another capability in Availity Essentials? When you use the new search option in Eligibility and Benefits Inquiry and see the eligibility and benefits details, the member’s current ID details will be available and allow you to transact within other digital capabilities where the member ID is required. Watch for more information on the Availity Essentials home page under News and Announcements to notify you when this feature is available. Get access to Availity Essentials nowIf you and your organization aren’t currently registered for Availity Essentials, now is the time to make that happen. Availity Essentials offers secure online access for working together and is free to our providers. To register, visit the availity.com Registration Information page. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan. NYBCBS-CM-025689-23-CPN25562 Clinical Criteria updates Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. On August 19, 2022, September 15, 2022, November 18, 2022, December 22, 2022, May 2, 2023, and May 19, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Empire BlueCross BlueShield HealthPlus (Empire). These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: Newly published criteria.
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Empire only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | September 29, 2023 | *CC-0237 | Qalsody (tofersen) | New | September 29, 2023 | *CC-0238 | Hydroxyprogesterone caproate | New | September 29, 2023 | *CC-0240 | Zynyz (retifanlimab-dlwr) | New | September 29, 2023 | CC-0165 | Trodelvy (sacituzumab govitecan) | Revised | September 29, 2023 | CC-0002 | Colony Stimulating Factor Agents | Revised | September 29, 2023 | CC-0128 | Tecentriq (atezolizumab) | Revised | September 29, 2023 | CC-0098 | Doxorubicin Liposome (Doxil, Lipodox) | Revised | September 29, 2023 | CC-0101 | Torisel (temsirolimus) | Revised | September 29, 2023 | CC-0107 | Bevacizumab for Non-Ophthalmologic Indications | Revised | September 29, 2023 | CC-0143 | Polivy (polatuzumab vedotin-piiq) | Revised | September 29, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised | September 29, 2023 | CC-0095 | Velcade (bortezomib) | Revised | September 29, 2023 | CC-0105 | Vectibix (panitumumab) | Revised | September 29, 2023 | CC-0178 | Synribo (omacetaxine mepesuccinate) | Revised | September 29, 2023 | CC-0114 | Jevtana (cabazitaxel) | Revised | September 29, 2023 | CC-0145 | Libtayo (cemiplimab-rwlc) | Revised | September 29, 2023 | *CC-0032 | Botulinum Toxin | Revised | September 29, 2023 | CC-0068 | Growth Hormone | Revised | September 29, 2023 | *CC-0057 | Krystexxa (pegloticase) | Revised | September 29, 2023 | *CC-0125 | Opdivo (nivolumab) | Revised | September 29, 2023 | *CC-0225 | Tzield (teplizumab-mzwv) | Revised | September 29, 2023 | *CC-0167 | Rituximab Agents for Oncologic Indications | Revised | September 29, 2023 | *CC-0075 | Rituximab Agents for Non-Oncologic Indications | Revised | September 29, 2023 | *CC-0182 | Iron Agents | Revised | September 29, 2023 | *CC-0124 | Keytruda (pembrolizumab) | Revised |
NYBCBS-CD-031930-23-CPN30759 Clinical Criteria updates Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. On December 22, 2022, May 2, 2023, and May 19, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Empire BlueCross BlueShield (Empire). These policies were developed, revised, or reviewed to support clinical coding edits. Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email. Please see the explanation/definition for each category of Clinical Criteria below: - New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff. Please note: - The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Empire only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised | September 11, 2023 | *CC-0237 | Qalsody (tofersen) | New | September 11, 2023 | *CC-0238 | Hydroxyprogesterone caproate | New | September 11, 2023 | *CC-0240 | Zynyz (retifanlimab-dlwr) | New | September 11, 2023 | CC-0165 | Trodelvy (sacituzumab govitecan) | Revised | September 11, 2023 | CC-0002 | Colony Stimulating Factor Agents | Revised | September 11, 2023 | CC-0128 | Tecentriq (atezolizumab) | Revised | September 11, 2023 | CC-0098 | Doxorubicin Liposome (Doxil, Lipodox) | Revised | September 11, 2023 | CC-0101 | Torisel (temsirolimus) | Revised | September 11, 2023 | CC-0107 | Bevacizumab for Non-Ophthalmologic Indications | Revised | September 11, 2023 | CC-0143 | Polivy (polatuzumab vedotin-piiq) | Revised | September 11, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised | September 11, 2023 | CC-0095 | Velcade (bortezomib) | Revised | September 11, 2023 | CC-0105 | Vectibix (panitumumab) | Revised | September 11, 2023 | CC-0178 | Synribo (omacetaxine mepesuccinate) | Revised | September 11, 2023 | CC-0114 | Jevtana (cabazitaxel) | Revised | September 11, 2023 | CC-0145 | Libtayo (cemiplimab-rwlc) | Revised | September 11, 2023 | *CC-0032 | Botulinum Toxin | Revised | September 11, 2023 | CC-0068 | Growth Hormone | Revised | September 11, 2023 | *CC-0057 | Krystexxa (pegloticase) | Revised | September 11, 2023 | *CC-0125 | Opdivo (nivolumab) | Revised | September 11, 2023 | *CC-0225 | Tzield (teplizumab-mzwv) | Revised | September 11, 2023 | *CC-0124 | Keytruda (pembrolizumab) | Revised |
NYBCBS-CR-031955-23-CPN30755 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. This guidance was published in 2020 by the New York State Department of Health. It provides details about billing for COVID-19 testing, specimen collection, and provided therapeutics. When submitting claims, ensure to follow the guidance below to avoid claim recoveries. Laboratory testing and specimen collectionProviders are reminded that Coronavirus (COVID-19) tests must be Food and Drug Administration (FDA)-approved or granted Emergency Use Authorization (EUA) through the FDA and in agreement with the level of complexity assigned by Wadsworth Laboratory to be eligible for reimbursement. COVID-19 test coverage for diagnostic and screening, including administration, must be consistent with the recommendations of the Centers for Disease Control and Prevention (CDC). *The fees and effective dates below are current as of December 2021. Providers should periodically check their respective fee schedules in eMedNY for updates through the eMedNY Provider Manuals web page. Complexity levels are available on the CDC Clinical Laboratory Improvement Amendments (CLIA) Test Complexities web page. Tests with EUA can be found on the FDA’s Emergency Use Authorizations for Medical Devices web page. Please note: COVID-19 test codes not outlined in this guidance are not covered. Individuals with signs or symptoms of COVID-19 should have diagnostic testing.The CDC also recommends testing for the following individuals listed on the CDC Overview of Testing for SARS-CoV-2, the virus that causes COVID-19 web page. Providers are reminded that, "all persons being tested, regardless of results, should receive counseling on the continuation of risk reduction behaviors that help prevent the transmission of SARS-CoV-2 (for example, wearing masks, physical distancing, and avoiding crowds and poorly ventilated spaces)" per CDC guidance. Additional information regarding risk reduction behaviors is available on the CDC COVID-19 Protect Yourself web page. Providers who are already receiving payment from another source for COVID-19 testing, specimen collection, or monoclonal antibody infusion are not eligible for reimbursement from Medicaid for those tests, specimen collections, or infusions. ReminderProviders are prohibited from charging Medicaid members a co-payment or any cost sharing responsibility for specimen collection or testing to diagnose or screen for COVID-19, or for monoclonal antibody infusions to treat a SARS-CoV-2 infection. Check the emergency indicator box on claims submissions to waive cost sharing for these services. Home-based testingCOVID-19 diagnostic tests with at-home sample collection are eligible for reimbursement when the criteria outlined in this guidance are met and the test is processed in a New York State (NYS)-approved laboratory. Additionally, over-the-counter (OTC) FDA-authorized COVID-19 diagnostic and screening tests that provide at-home results are eligible for reimbursement during the public health emergency (PHE). For details on coverage of point-of-care tests with at-home results and no member cost sharing, please refer to the New York State (NYS) Medicaid Pharmacy Policy and Billing Guidance for At Home COVID-19 Testing. Molecular/polymerase chain reaction (pcr) tests:- 87635 (effective March 13, 2020) — Infectious agent detection by nucleic acid deoxyribonucleic acid (DNA) or ribonucleic acid (RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), amplified probe technique:
- U0002 (effective March 13, 2020) — 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCov (COVID-19), any technique, multiple types, or subtypes (includes all targets), non-CDC:
High throughput testsThese tests use highly sophisticated throughput machines, which require more intensive technician training (to ensure the role of extremely skilled personnel) and more time intensive processes (to assure quality). A high throughput technology uses a platform that employs automated processing of more than two hundred specimens a day. It is noted throughout the CMS-Ruling 2020-1-R document, that U0003 should identify tests that would otherwise be identified by CPT ® code 87635 but for being performed with these high throughput technologies. U0004 should identify tests that would otherwise be identified by U0002 but for being performed with these high throughput technologies. Additionally, neither U0003 nor U0004 should be used for tests that detect COVID-19 antibodies: - U0003 (effective April 14, 2020) — infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R:
- FFS fee = $100 (until December 31, 2020), $75 (as of January 1, 2021)
- U0004 (effective April 14, 2020) — 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCov (COVID-19), any technique, multiple types, or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R:
- FFS fee = $100 (until December 31, 2020), $75 (as of January 1, 2021)
In accordance with CMS, the fees for high throughput tests were reduced to $75 effective January 1, 2021. For dates of service on or after January 1, 2021, U0005 may be billed as an add on code, when appropriate: - U0005 (effective January 1, 2021) — Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease COVID-19), amplified probe technique, CDC, or non-CDC, making use of high throughput technologies, completed within two calendar days from date of specimen collection (List separately in addition to either HCPCS code U0003 or U0004) as described by CMS-2020-01-R2.
Antigen tests:- 87426 (effective June 25, 2020) — Infectious agent antigen detection by immunoassay technique, (for example, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method); severe acute respiratory syndrome coronavirus (for example, SARS-CoV-2, SARS-CoV-2 COVID-19):
- 87811 (effective October 6, 2020) — Infectious agent antigen detection by immunoassay with direct optical (in other words, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19):
Multiplex tests:- 87428 (effective November 10, 2020) — Infectious agent antigen detection by immunoassay technique, (for example, enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), immunochemiluminometric assay (IMCA) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (for example, SARS-CoV-2, SARS-CoV-2 COVID-19) and influenza virus types a and b:
- 87636 (effective October 6, 2020) — Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) and influenza virus types a and b, multiplex amplified probe technique:
- 87637 (effective December 1, 2021) — Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)), influenza virus types a and b, and respiratory syncytial virus, multiplex amplified probe technique:
Antibody testsPlease refer to the following web page for information on antibody testing for NYS residents through the FDA: "Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination: FDA Safety Communication:” - 86328 (effective April 10, 2020) — Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (for example, reagent strip), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19):
- 86769 (effective April 10, 2020) — Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19):
Specimen Collection (effective May 22, 2020): During the period of the emergency, separate Medicaid reimbursement is available for specimen collection when this is the only service being performed. Providers billing for reimbursement of one of the above tests should not bill separately for specimen collection or report. These specimen collection components are included in reimbursement for the test. Providers and clinics billing for other primary procedures for the same patient on the same day should not bill for specimen collection. For more information, please refer to the table below. Federally Qualified Health Center (FQHC) and Non-FQHC COVID-19 Specimen Collection | Code | Description | Practitioner/ Clinic (Non-FQHC) reimbursement | FQHC reimbursement | G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavir us disease [COVID-19]) | $23.46 | Physician/PA/NP/Midwife: bill rate code "4012" when specimen collection only is provided. Offsite visit rate ($64.97 upstate/$72.73 downstate) will be paid. Physician/PA/NP/Midwife: bill rate code "4013" when specimen collection and E&M are provided. Full PPS rate will be paid. RN/LPN: bill procedure code "G2023" (ordered ambulatory) for specimen collection only. A fee of $23.46 will be paid. All FQHC services in this chart are eligible for wrap payments. |
Clinics should bill the codes outlined in this guidance via the ordered ambulatory fee schedule. The COVID-19 test and specimen collection codes are not payable under ambulatory patient groups (APGs). For additional details, please refer to the state guidance: COVID-19 Guidance for Medicaid Providers (ny.gov). Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Empire BlueCross BlueShield (Empire), in conjunction with designee, CERiS,* will begin performing line item facility claim reviews. CERiS’ professional review process identifies errors, unrelated charges, and non-separately billable charges on facility claims for inpatient services, on a prepayment basis. Claims should be billed and appropriately coded according to Empire policies along with industry standard coding guidelines for the applicable bill type (including but not limited to UB Editor, AMA, CPT, CPT Assistant, HCPCS, DRG guidelines, CMS’ National Correct Coding Initiative (CCI) Policy Manual, CCI table edits and other CMS guidelines). CERiS may request documentation, such as an itemized bill, to conduct the professional review. Once contacted, please submit requested information within seven calendar days. Empire and CERiS may accept additional documentation from the provider such as other documents substantiating the treatment or health service or delivery of supplies; provider’s established internal policies; or business practices justifying the healthcare service or supply. * CERiS is an independent company providing claim service review on behalf of the health plan. NYBCBS-CR-026331-23-SRS26331, NYBCBS-CR-032596-23-SRS32506 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. In accordance with Chapter 645 of the Laws of 2005, the New York State Medicaid program does not cover prescription or physician administered drugs used for the treatment of sexual dysfunction (SD) or erectile dysfunction (ED). Additionally, Medicaid does not reimburse any supplies or procedures used to treat SD/ED for persons required to register as sex offenders. Providers must verify that Medicaid members receiving any procedures or supplies that may be used for these indications are not listed as registered sex offenders. Medicaid Managed Care (MMC) plansPrior to approving requests for any SD/ED related drugs, supplies, or procedures, MMC plans (including mainstream MMC plans, HIV Special Needs Plans [SNPs], and Health and Recovery Plan [HARP] programs) are required to submit requests for information regarding enrollee status on the sex offender registry to the New York State Department of Health through the Health Commerce System (HCS) Erectile Dysfunction Verification System (EDVS) each time there are requests for these services. New York State Medicaid fee-for-service has compiled the following list of services used for the treatment of SD/ED: CPT® codes and physician-administered (J‑code) drugs | Description | 37788 | Penile revascularization, artery, with or without vein graft | 37790 | Penile venous occlusive procedure | 54400 | Insertion of penile prosthesis; non-inflatable (semi-rigid) | 54401 | Insertion of penile prosthesis; inflatable (self-contained) | 54405 | Insertion of multi-component, inflatable penile prosthesis, including placement of pump, cylinders, and reservoir | 54408 | Repair of component(s) of a multi-component, inflatable penile prosthesis | 54410 | Removal and replacement of all component(s) of a multi-component, inflatable penile prosthesis at the same operative session | 54411 | Removal and replacement of all components of a multi-component inflatable penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue | 54416 | Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis at the same operative session | 54417 | Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue | 55870 | Electroejaculation | J0270 | Injection, alprostadil, 1.25 mcg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) * | J0275 | Alprostadil urethral suppository (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered) * | J0775 | Injection, collagenase, clostridium histolyticum, 0.01 mg | J2440 | Injection, papaverine hydrochloride injection (HCI), up to 60 mg | J2760 | Injection, phentolamine mesylate, up to 5 mg | L7900 | Male vacuum erection system | L7902 | Tension ring, for vacuum erection device, any type, replacement only, each |
* Please note: In the inpatient setting, alprostadil and papaverine may be covered for the treatment of a condition other than sexual or erectile dysfunction for which the drugs have been approved by the FDA. Additionally, physician-administered collagenase, clostridium histolyticum, and phentolamine mesylate may be covered for the treatment of a condition, other than sexual or erectile dysfunction, for which the drug has been approved by the FDA and prior approval has been received. All the above codes need to be checked in the state system before they are reviewed for medical necessity. Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. This article has been updated to remove archived criteria CG-SURG-27. Please see updated article here. The following services will be added to precertification for the effective dates listed below. To obtain precertification, providers can access Availity Essentials* (Availity.com) or call Empire BlueCross BlueShield’s Utilization Management department using the number on the back of the member’s identification card. Service preapproval is based on member’s benefit plan/eligibility at the time the service is reviewed/approved. Precertification can help avoid unnecessary charges or penalties by helping to ensure that the member's care is medically necessary and administered at an appropriate network facility and by a network provider. Add to precertification | Criteria | Criteria description | Code | Effective date | CG-SURG-27 | Gender Affirming Surgery | 15769 | 12/01/2023 | CG-SURG-88 | Mastectomy for Gynecomastia | 19300 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 19303 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 53410 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 53420 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 53425 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 53430 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 54400 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 57426 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 58150 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 58571 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 58572 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | 58573 | 12/01/2023 | CG-SURG-27 | Gender Affirming Surgery | C1813 | 12/01/2023 | CG-SURG-09 | Temporomandibular Disorders | D7899 | 12/01/2023 | CG-SURG-09 | Temporomandibular Disorders | D9950 | 12/01/2023 | CG-SURG-09 | Temporomandibular Disorders | D9951 | 12/01/2023 | CG-SURG-09 | Temporomandibular Disorders | D9952 | 12/01/2023 | CG-DME-45 | Ultrasound Bone Growth Stimulation | E0760 | 12/01/2023 | CG-DME-06 | Compression Devices for Lymphedema | K1024 | 12/01/2023 | CG-DME-06 | Compression Devices for Lymphedema | K1025 | 12/01/2023 |
* Availity, LLC is an independent company providing administrative support services on behalf of the health plan. UM AROW #4605 Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-034405-23-SRS33553 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective December 29, 2023, Carelon Medical Benefits Management, Inc.,* a separate company, will expand the Musculoskeletal Program to perform medical necessity/clinical appropriateness reviews for: - The requested site of service for certain spine, joint, and interventional pain procedures.
- Monitored anesthesia or conscious sedation (MAC), when requested in conjunction with interventional pain codes.
This Musculoskeletal Program applies to fully insured members of Empire BlueCross BlueShield (Empire) as outlined below. Please note, these reviews do not apply to procedures performed on an emergent basis. Carelon Medical Benefits Management will use the following Clinical Guidelines when performing these reviews. The Clinical Criteria to be used can be found by accessing the links below: Clinical Appropriateness Guidelines Surgical Appropriate Use Criteria: Site of Service CG-MED-78: Anesthesia Services for Interventional Pain Management Procedures. Site of care reviewsCarelon Medical Benefits Management will continue to manage the Musculoskeletal Program and level of care review. The Level of Care Guideline for Musculoskeletal Surgery and Procedures is used for the level of care review. A subset of the Carelon Medical Benefits Management Musculoskeletal Program codes will be reviewed for site of care. A complete list of CPT® codes requiring prior authorization for the Musculoskeletal Site of Care program is available on the Carelon Medical Benefits Management Musculoskeletal microsite. MAC reviewsThe codes that will be reviewed are 01991, 01992, 01937, 01938, 01939, and 01940. A complete list of CPT® codes requiring prior authorization for the Monitored Anesthesia Care for Interventional Pain program is available on the Carelon Medical Benefits Management Musculoskeletal microsite. If you have a member in a current course of treatment for pain management where services were approved without reviewing the MAC, identify the member for us at the next request. Site of care review may also apply if these procedures are requested in a hospital outpatient department and could safely be done in an ambulatory surgery center. The anesthesiologist may determine that a member requires monitored anesthesia on the day of service. A retrospective review may be requested, or a post service claim may be submitted with a clinical record including the pre-anesthesia assessment, the patient’s medical history documenting that patient meets criteria for MAC, and a detailed description of the procedure performed for Carelon Medical Benefits Management to determine coverage for the service as medically necessary. Members included in the programAll fully insured members currently participating in the Carelon Medical Benefits Management Musculoskeletal Program are included. This program will be offered to self-funded (ASO) groups that currently participate in the Musculoskeletal Program to add to their members’ benefit package as of December 29, 2023. To determine if prior authorization for the Carelon Medical Benefits Management Musculoskeletal Program applies to an Empire member, contact the Provider Services phone number on the back of the member’s ID card. The following members are excluded: Medicare Advantage (individual and group), Medicaid, Medicare, Medicare supplement, and the Federal Employee Program® (FEP®). Prior authorization requirementsFor services scheduled to begin on or after December 29, 2023, care providers must contact Carelon Medical Benefits Management to obtain prior authorization. Ordering and servicing care providers may begin contacting Carelon Medical Benefits Management on December 18, 2023. Care providers may submit prior authorization requests to Carelon Medical Benefits Management in one of several ways: - Access ProviderPortal directly at providerportal.com. Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization. Initiating a request on ProviderPortal and entering all the requested clinical questions will allow you to receive an immediate determination.
- Access Carelon Medical Benefits Management via the Availity Essentials* platform at Availity.com.
- Call the Carelon Medical Benefits Management Contact Center toll-free number at 866-714-1107, Monday through Friday, 8 a.m. to 5 p.m.
- The Musculoskeletal Program microsite helps you learn more and access helpful information and tools such as order entry checklists.
Note: If a care provider office attempts to use the Interactive Care Reviewer (ICR) tool on the Availity Essentials platform to prior authorize an outpatient musculoskeletal case, ICR will produce a message referring the care provider to Carelon Medical Benefits Management (ICR cannot accept prior authorization requests for services administered by Carelon Medical Benefits Management). Musculoskeletal Site of Care and MAC training webinarsWe invite you to take advantage of a free informational webinar that will introduce you to the program and the robust capabilities of the Carelon Medical Benefits Management ProviderPortal. Go to the Musculoskeletal Program microsite to register for an upcoming webinar. If you have previously registered for other services managed by Carelon Medical Benefits Management, there is no need to register again. We value your participation in our network and look forward to working with you to improve the health of our members. * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Availity, LLC is an independent company providing administrative support services on behalf of the health plan. NYBCBS-CM-034613-23 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. For services beginning on December 1, 2023, prior authorization requests for admission to or concurrent stay in a skilled nursing facility (SNF), an inpatient acute rehab facility (IRF), or a long-term acute care hospital (LTACH) for members of most Commercial plans1 will be reviewed by Carelon Post-Acute Solutions, LLC (formerly myNEXUS [Carelon LLC]).2 Through this program, Carelon LLC clinicians will collaborate with caregivers and facility care managers/discharge planners to provide transition planning as well as the pre-service and concurrent review authorizations of post-acute care services. The goal of this program is to support members through their recovery process in the most appropriate environment. With this program implementation, Empire BlueCross BlueShield will transition to Carelon LLC Clinical Appropriateness Guidelines. The guideline can be accessed here. Members included in the PAC Review ProgramLocal Commercial fully insured and ASO members. Members of the following products are excluded: National Accounts, HealthLink, California HMO, New York HMO, State of New York, City of New York, 32BJ, New York Hotel Trades, JAA, Blue Card Host, Federal Employee Program® (FEP®). How to submit or check a prior authorization requestFor SNF, IRF, or LTACH admissions, Carelon LLC will begin receiving requests on Tuesday, November 28, 2023, for members whose anticipated discharge date is December 1, 2023, or after. Providers are encouraged to request authorization using NexLync. Go to the Carelon LLC website to get started. You can upload clinical information and check the status of your requests through this online tool seven days a week, 24 hours a day. If you are unable to use the link or website, you can call the Carelon LLC Provider Call Center at 833-431-0780 during normal operating hours from 7 a.m. to 7 p.m. CT, Monday through Friday. To learn more about Carelon PAS and upcoming training webinars, visit PAC-IM Program - Carelon Post Acute Solutions (carelonmedicalbenefitsmanagement.com) or email PACproviderrelations@carelon.com. If you have additional questions, please call the Carelon LLC Provider Call Center at 833-431-0780. 1An up-to-date list of in-scope plans will be maintained on the Carelon Post-Acute Solutions web site. 2Concurrent stay review requests for members admitted to SNF, IRF, or LTACH facilities prior to December 1, 2023, should be directed to the health plan.
* Carelon Post-Acute Solutions is an independent company providing post-acute benefits management services on behalf of the health plan. NYBCBS-CM-034710-23 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective for dates of service on and after December 1, 2023, the following codes will require prior authorization through Carelon Medical Benefits Management, Inc.* (formerly AIM Specialty Health®). CPT® code | Description | 0042T | Cerebral Perfusion Analysis Using Computed Tomography with Contrast Administration, Including Post-Processing of Parametric Maps with Determination of Cerebral Blood Flow, Cerebral Blood Volume, and Mean Transit Time |
As a reminder, ordering and servicing providers may submit prior authorization requests to Carelon in one of several ways: - Access Carelon’s ProviderPortalSM directly at www.providerportal.com:
- Online access is available 24/7 to process orders in real-time and is the fastest and most convenient way to request authorization.
- Access Carelon via the Availity Essentials* website at www.availity.com.
Note: This update does not apply to the Federal Employee Program®. If you have any questions related to guidelines, please contact Carelon via email at MedicalBenefitsManagement.guidelines@Carelon.com. Additionally, you may access and download a copy of the current and upcoming guidelines here. * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Availity, LLC is an independent company providing administrative support services on behalf of the health plan. NYBCBS-CRCM-025224-23-CPN25171 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective September 1, 2023, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Empire BlueCross BlueShield HealthPlus for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines (including definitions and specific contract provisions/exclusions) take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Code description | A0888 | Noncovered Ambulance Mileage | E0465 | Home ventilator, any type, used with invasive interface, (for example, tracheostomy tube) | E0467 | Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components, and supplies for all functions | E2500 | Speech generating device, digitized speech, using pre-recorded messages, 8 min. or less | E2502 | Speech generating device, digitized speech, using pre-recorded messages, 8-20 min. | E2506 | Speech generating device, digitized speech, using pre-recorded messages, over 40 min. | E2508 | Speech generating device, synthesized speech, requiring message formulation by spelling | E2512 | Accessory for speech generating device, mounting system |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity Essentials* at https://availity.com
- Fax: 800-964-3627
- Phone: 800-450-8753
Not all PA requirements are listed here. Detailed PA requirements are available to providers at https://mediprovider.empireblue.com/new-york-empire-provider/communications/news-and-announcements on the Resources tab or, for contracted providers, by accessing Availity.com. Providers may also call Provider Services at 800-450-8753 for assistance with PA requirements. UM AROW #4230
* Availity, LLC is an independent company providing administrative support services on behalf of the health plan. NYBCBS-CD-023886-23-CPN23495 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective October 1, 2023, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Empire BlueCross BlueShield HealthPlus for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Code description | 69706 | Nasopharyngoscopy, surgical, with dilation of eustachian tube (in other words, balloon dilation); bilateral |
To request PA, you may use one of the following methods: - Web: Once logged in to Availity* at availity.com.
- Fax: 800-964-3627
- Phone: 800-450-8753
Not all PA requirements are listed here. Detailed PA requirements are available to providers on providerpublic.empireblue.com on the Resources tab or for contracted providers by accessing availity.com. Providers may also call Provider Services at 800-450-8753 for assistance with PA requirements. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan.
UM AROW #4500 NYBCBS-CD-028264-23-CPN27261 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective December 1, 2023, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Empire BlueCross BlueShield for Medicare members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Code description | 64581 | Incision for implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) | 64628 | Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral | C1764 | Event recorder, cardiac (implantable) | E0466 | Home ventilator, any type, used with non-invasive interface, (for example, mask, chest shell) | E0766 | Electrical stimulation device used for cancer treatment, includes all accessories, any type | L5845 | Knee-Shin Sys Stance Flexion | L5910 | Endo Below Knee Alignable Sy |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on empireblue.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com.* Providers may also call the number on the back of the member’s ID card for assistance with PA requirements. * Availity, LLC is an independent company providing administrative support services on behalf of the health plan.
UM AROW# 4489 NYBCBS-CR-028206-23-CPN27653 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Beginning with dates of service on or after December 1, 2023, Empire BlueCross BlueShield will expand the current Documentation Standards for Episodes of Care — Professional reimbursement policy to apply to facility providers. This policy outlines how and what elements must be documented for an episode of care. The policy will be retitled Documentation Standards for Episodes of Care — Professional and Facility. For specific policy details, visit the reimbursement policy page, at empireblue.com. NYBCBS-CM-034780-23-CPN34758 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Beginning with dates of service on or after December 1, 2023, Empire BlueCross BlueShield will update the Place of Service – Facility reimbursement policy to include professional services billed under revenue codes 960-983 expanded to 960-989. According to the policy, Evaluation & Management (E/M) services and other professional services: - Must be billed on a CMS-1500 claim form; and
- Are not reimbursable if billed on a UB-04 claim form (excluding E/M services rendered in an emergency room and billed with emergency room revenue codes).
The policy will be retitled Facility Guidelines for Claims related to Professional Services – Facility. For specific policy details, visit the reimbursement policy page at empireblue.com. NYBCBS-CM-034777-23-CPN34757 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. In the July 2023 edition of Provider News, Empire BlueCross BlueShield announced multiple updates to the Prolonged Services – Professional reimbursement policy effective October 1, 2023. To clarify, the update to “remove language requiring providers to report start and stop times for reimbursement eligibility” was effective as of May 19, 2023. For specific policy details, visit empireblue.com/provider/policies/reimbursement/. Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective as of June 14, 2023, Empire BlueCross BlueShield updated the Documentation and Reporting Guidelines for Evaluation and Management (E/M) Services reimbursement policy to include the 2021 American Medical Association (AMA) CPT® Level of Medical Decision Making (MDM) table to align with the 2021-2023 Centers for Medicare & Medicaid Services (CMS) and AMA-CPT code changes. This table will be listed under the policy section titled Selecting a Level of Medical Decision Making for Coding an E/M Service. When determining the level of E/M service using MDM, this table will be used instead of the 1995/1997 CMS risk tables and the Marshfield Clinic tables. Additional updates to this reimbursement policy are as follows: - Documentation submitted in accordance with this reimbursement policy will remain subject to signature and other requirements as stated in the related Documentation for Episodes of Care reimbursement policy. Therefore, the policy was updated to include the following note: All documents are subject to the Documentation Requirements for Episodes of Care policy.
- The Related Coding section was expanded to include other E/M services, as defined in the policy.
For specific policy details, visit the reimbursement policy page. Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Oral health is essential to general health and well-being. Poor dental health can cause oral cancer, gum disease, tooth loss, bad breath, and dental decay. It can also lead to: - Heart disease — Those with gum disease are two-times more likely to have or develop heart disease.1
- Strokes and clots — Those with gum disease have an increased susceptibility of having a stroke and/or developing blood clots.1
- Respiratory disease — Harmful bacteria from the mouth can serve as an agent for pneumonia and bronchitis.2
- Kidney disease — Harmful bacteria from poor oral hygiene can weaken kidneys.3
- Pancreas — Research suggests a significant association between gum disease and pancreatic cancer.4
- Diabetes — Gum disease disrupts the control of blood sugar. Gum disease can be more severe and take longer to heal for someone with diabetes.5
- Mental illness — There is an explicit link between mental health and oral health, including tooth loss due to gum disease and tooth decay. Those with mental illness often experience dental phobia, tooth erosion from eating disorders, and dry mouth from medications. This can be a reciprocal relationship.6
- Poor pregnancy outcomes — Nearly 65% to 75% of pregnant women have gingivitis (from changing hormones during pregnancy). If not treated, this can lead to poor pregnancy outcomes for mother and baby, including preterm birth and low birth weight.7
What you can do:- Make it regular practice to ask your patients if they go to the dentist.
- Perform an oral inspection at every visit.
- Have dental provider resources readily available; our participating dental provider for Medicaid Managed Care and Child Health Plus members is Liberty Dental.*
- Help your patients consider the consequences of poor oral health (especially since the COVID-19 pandemic) by encouraging preventive dental visits at least once a year.
- Recognize social and cultural disparities that can contribute to poor oral health.
- Provide fluoride varnish for children in the primary care setting.8 This application is reimbursable to physicians and nurse practitioners with proper CPT® coding.
If you have questions, visit the Contact Us section at the bottom of our provider website (for up-to-date contact information or call Provider Services at 800-450-8753. References
1 Mayo Clinic website: Oral health: A window to your overall health (accessed January 2023): mayoclinic.org. 2 National Library of Medicine website: Oral health and respiratory infection (accessed January 2023): ncbi.nlm.nih.gov. 3 Akar H, Akar, GC, Carrero JJ, Stenvinkel P, Lindholm, B: Systemic Consequences of Poor Oral Health in Chronic Kidney Disease Patients. Clinical Journal of the American Society of Nephrology (January 2011): https://journals.lww.com/CJASN | DOI: 10.2215/CJN.05470610. 4 National Library of Medicine website: Oral Health in Relation to Pancreatic Cancer Risk in African American Women (accessed January 2023): ncbi.nlm.nih.gov. 5 Centers for Disease Control and Prevention: Diabetes and Oral Health (accessed January 2023): cdc.gov. 6 Oral Health Foundation: Mental illness and oral health (accessed January 2023): dentalhealth.org. 7 Corbella S, Taschieri S, Del Fabbro M, Francetti L, Weinstein R, Ferrazzi E: Adverse pregnancy outcomes and periodontitis: A systematic review and meta-analysis exploring potential association. Quintessence International (March 2016): quintessence-publishing.com | DOI: 10.3290/j.qi.a34980. 8 New York State Department of Health website: Improving the Oral Health of Young Children: Fluoride Varnish Training Materials and Oral Health Information for Child Health Care Providers (accessed January 2023): https://health.ny.gov.
* Liberty Dental is an independent company providing dental benefit management services on behalf of the health plan. NYBCBS-CD-031893-23 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. The Empire BlueCross BlueShield (Empire) pre-service clinical review of non-oncology specialty pharmacy drugs will be managed by the Medical Specialty Drug Review team of Empire. Oncology drugs will be managed by Carelon Medical Benefits Management, Inc.,* a separate company. The following Clinical Criteria documents were endorsed at the June 12, 2023, Clinical Criteria meeting. To access the Clinical Criteria information, visit this link. New Clinical Criteria effective December 1, 2023The following Clinical Criteria are new: • CC-0241 Elfabrio (pegunigalsidase alfa-iwxj) • CC-0242 Epkinly (epcoritamab-bysp) • CC-0243 Vyjuvek (beremagene geperpavec) Revised Clinical Criteria effective December 1, 2023The following Clinical Criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary: • CC-0015 Infertility and HCG Agents • CC-0061 Gonadotropin Releasing Hormone Analogs for the Treatment of Non-Oncologic Indications • CC-0062 Tumor Necrosis Factor Antagonists • CC-0177 Zilretta (triamcinolone acetonide extended-release) * Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. NYBCBS-CM-034114-23-SRS34114 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective April 5, 2023, Sublocade® can no longer be filled at Accredo Specialty Pharmacy.* Members currently filling through Accredo Specialty Pharmacy will need to switch to CVS Specialty Pharmacy.* A member of the CVS Specialty Pharmacy Care team will be contacting prescribers to obtain a new prescription. Prescribers can contact CVS Specialty Pharmacy at 877-254-0015. * Accredo Specialty Pharmacy is an independent company providing pharmacy services on behalf of the health plan. CVS is an independent company providing pharmacy services on behalf of the health plan. NYBCBS-CM-034783-23-CPN34761 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Specialty pharmacy updates for Empire BlueCross BlueShield (Empire) are listed below. Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the Empire Medical Specialty Drug Review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc.*, a separate company. Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications. Including the National Drug Code (NDC) code on your claim may help expedite claim processing of drugs billed with a not otherwise classified (NOC) code. Prior authorization updatesEffective for dates of service on and after December 1, 2023, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process. Access our Clinical Criteria to view the complete information for these site of prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® code(s) | CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | J3490, J3590 | CC-0242* | Epkinly (epcoritamab-bysp) | C9399, J3490, J3590, J9999 | CC-0243 | Vyjuvek (beremagene geperpavec) | J3490, J3590 | CC-0062 | Yuflyma (adalimumab-aaty) | J3490, J3590 |
* Oncology use is managed by Carelon Medical Benefits Management. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Quantity limit updatesEffective for dates of service on and after December 1, 2023, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT® Code(s) | CC-0241 | Elfabrio (pegunigalsidase alfa-iwxj) | J3490, J3590 | CC-0228 | Leqembi (lecanemab) | J0174 | CC-0243 | Vyjuvek (beremagene geperpavec) | J3490, J3590 | CC-0062 | Yuflyma (adalimumab-aaty) | J3490, J3590 |
* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. NYBCBS-CM-034763-23-CPN34723 Prior authorization updates for medications billed under the medical benefit Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Effective for dates of service on and after September 1, 2023, the following medication codes billed on medical claims will require prior authorization in accordance with the requirements of the current or new Clinical Criteria documents. Please note, inclusion of a national drug code on your medical claim is necessary for claims processing. Visit the Clinical Criteria website to search for the following specific Clinical Criteria listed. Clinical Criteria | HCPCS or CPT® code(s) | Drug name | CC-0065 | C9399, J7199 | Altuviiio (antihemophilic factor recombinant) |
What if I need assistance?If you have questions about this communication or need assistance with any other item, contact your local Provider Relationship Management representative or call Provider Services at 800-450-8753. Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. NYBCBS-CD-028797-23-CPN28733 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. The following Part B medications from the current Clinical Criteria Guidelines are included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review (as is current procedure). Step therapy will not apply for members who are actively receiving medications listed below. There are no clinical changes to Clinical Criteria CC-005, Hyaluronan Injections. Based on feedback, the table listing the preferred and non-preferred products has been updated to present the information in a more useful manner. The updated table identifies preferred alternatives based on injection series. Clinical Criteria Guidelines are publicly available on the provider website. Visit the Clinical Criteria page to search for specific criteria. Clinical UM Guidelines | Preferred drug(s) | Nonpreferred drug(s) | CC-0005 | Single injection: Durolane Three injection series: Euflexxa Gel-Syn Five injection series: Supartz | Single injection: Gel-One Monovisc Synvisc-one Two injection series: Hymovis Three Injection series: Orthovisc Synojoynt Synvisc Triluron Trivisc Five injection series: Genvisc 850 Hyalgan Visco-3 |
NYBCBS-CR-031136-23-CPN30365 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. **This collateral ran originally in the July 1, 2023, newsletter and was also posted on the provider portal with an October 1, 2023, effective date. The new date of service will begin on November 1, 2023.** Effective for dates of service on and after November 1, 2023, the specialty Medicare Part B drug listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims. HCPCS or CPT® codes | Medicare Part B drugs | J1931 | Aldurazyme (laronidase) | J0256 | Aralast NP (alpha-1 proteinase inhibitor), Prolastin-C (alpha-1 proteinase inhibitor), Zemaira (alpha-1 proteinase inhibitor) | J1786 | Cerezyme (imiglucerase) | J0584 | Crysvita (burosumab-twza) | J1743 | Elaprase (idursulfase) | J3060 | Elelyso (taliglucerase) | J0180 | Fabrazyme (agalsidase beta) | J0257 | Glassia (alpha-1 proteinase inhibitor) | J0638 | Ilaris (canakinumab) | J0221 | Lumizyme (alglucosidase alfa) | J3397 | Mepsevii (vestronidase alfa) | J1458 | Naglazyme (galsulfase) | J0219 | Nexviazyme (avalglucosidase alfa-ngpt) | J0222 | Onpattro (patisiran) | J1322 | Vimizim (elosulfase alfa) | J3385 | Vpriv (velaglucerase) | J0775 | Xiaflex (collagenase clostridium histolyticum) |
NYBCBS-CR-032245-23-CPN31947 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. The American Cancer Society (ACS) recommends annual fecal immunochemical test (FIT) kit testing for all adults aged 45 and older with average risk for colon cancer. For these patients, the FIT kit is a convenient, cost effective, and discreet testing option.1, 2 FIT kits offer a cost effective, highly accurate option for colorectal cancer screeningScreening with FIT kits is convenient and easier than ever. Adopting FIT screening into your practice can help increase patient adherence to colon cancer screening recommendations. Annual FIT improves screening rates and has also been shown to save lives.3 Empire BlueCross BlueShield HealthPlus physicians and their patients have access to high-quality, low-cost colorectal cancer screening FIT kits through our National Lab partners Labcorp* and Quest Diagnostics*. If you have specific questions, please contact the labs directly: Labcorp: ColoFIT™, 855-LABCORP (855-522-2677), labcorp.com; labcorp.com/cancer/colorectal/providers: To find Labcorp, Quest Diagnostics, and other participating labs in your patient’s plan network, select Find Care from the Provider Resources menu at anthem.com. References: 1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin.2018;68(4):250-281. 2. Occult blood, fecal, immunoassay. Laboratory Corporation of America Holdings and Lexi-Comp Inc. 2021. Accessed April 11, 2022.https://www.labcorp.com/tests/182949/occult-blood-fecal-immunoassay. 3. Dougherty MK, Brenner AT, Crockett SD, et al. Evaluation of interventions intended to increase colorectal cancer screening rates in the United States: a systematic review and meta-analysis.JAMA Intern Med.2018;178(12):1645-1658.
*Labcorp is an independent company providing lab services on behalf of the health plan. Quest Diagnostics is an independent company providing lab services on behalf of the health plan. NYBCBS-CD-034186-23 Beginning January 1, 2024, Empire became Anthem. This article, published under the former brand, now applies to Anthem. Empire BlueCross BlueShield providers for Medicare Advantage medication reconciliation. Please see the FAQ to learn how to receive reimbursement for post inpatient discharge medication reconciliation. |